Physician profile
Carmen Espitia
NPI 1811998636
$5,589.47
in general payments reported to CMS, 2019-2025
23 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $362 · 2021: $886 · 2022: $1,269 · 2023: $733 · 2024: $879 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.27 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,344.59 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $893.54 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $644.43 | 2019-2025 | Xifaxan |
| Corcept Therapeutics | $411.04 | 2021-2023 | Korlym |
| Lilly USA, LLC | $347.32 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.42 | 2022-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $274.89 | 2019-2022 | |
| Abbvie INC. | $273.70 | 2021-2023 | |
| Amgen INC. | $199.85 | 2023-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $160.54 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $159.93 | 2019-2022 | |
| Boston Scientific Corporation | $113.84 | 2021 | |
| Astellas Pharma US INC | $73.31 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $68.54 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $51.43 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $50.33 | 2020-2024 | Zoryve |
| Glaxosmithkline, LLC. | $34.77 | 2022-2023 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $28.75 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $27.73 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $27.30 | 2019 | |
| Biogen, INC. | $25.08 | 2019 | |
| Abbott Laboratories | $23.80 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Espitia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.